The Aplastic Anemia & MDS International Foundation (AA&MDSIF) is endorsing the clinical development of Amyndas’ lead candidate AMY-101, as a novel treatment for paroxysmal nocturnal hemoglobinuria (PNH). The AA&MDSIF has awarded Dr. Risitano (Federico II University) and Dr. Calado (University of Sao Paolo) a grant to fund the first clinical trial of AMY-101 in untreated PNH patients. Both are distinguished experts in PNH research. Following extensive pre-clinical development and evaluation, AMY-101 was found to provide complete and sustained complement inhibition. The C3 complement inhibitor is expected to be effective in patients suffering from PNH, even those who do not fully benefit from the current complement-directed standard treatment.
To read entire press release: www.fiercepharma.com